Literature DB >> 7039758

Randomized controlled trial of colestipol in antibiotic-associated colitis.

G A Mogg, R H George, D Youngs, M Johnson, H Thompson, D W Burdon, M R Keighley.   

Abstract

Thirty-eight patients with severe antibiotic-associated postoperative diarrhoea were entered into a randomized controlled trial to compare colestipol (an ion exchange resin) in 17 patients with placebo (sherbet) in 21 patients. Clostridium difficile or its toxin was present before treatment in 12 of the colestipol group, compared with only 5 in the placebo group. Because of the low incidence of Cl. difficile or its toxin, the placebo group data from 22 patients receiving placebo in a previous trial (9 of whom had Cl. difficile or toxin) were included for comparison. Neither colestipol nor placebo had any influence on the faecal excretion of Cl. difficile or its toxin. Colestipol was clinically no better than placebo. In view of the persistent faecal excretion of Cl. difficile toxin, ion exchange resins cannot be recommended for the treatment of antibiotic-associated colitis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039758     DOI: 10.1002/bjs.1800690306

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

Review 1.  Understanding the mechanisms of faecal microbiota transplantation.

Authors:  Alexander Khoruts; Michael J Sadowsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-22       Impact factor: 46.802

Review 2.  Management of adult Clostridium difficile digestive contaminations: a literature review.

Authors:  Fanny Mathias; Christophe Curti; Marc Montana; Charléric Bornet; Patrice Vanelle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-29       Impact factor: 3.267

Review 3.  Clostridium difficile-associated disease: changing epidemiology and implications for management.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  New antimicrobial agents for patients with Clostridium difficile infections.

Authors:  John G Bartlett
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 5.  Clostridium difficile infection: a re-emerging threat.

Authors:  Hitoshi Honda; Erik R Dubberke
Journal:  Mo Med       Date:  2009 Jul-Aug

6.  Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii.

Authors:  R D Toothaker; G W Elmer
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 7.  Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.

Authors:  Stefano Di Bella; Paolo Ascenzi; Steven Siarakas; Nicola Petrosillo; Alessandra di Masi
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

8.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

Review 9.  Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015.

Authors:  Joana Carmo; Susana Marques; Iolanda Chapim; Maria Ana Túlio; José Pedro Rodrigues; Miguel Bispo; Cristina Chagas
Journal:  GE Port J Gastroenterol       Date:  2015-08-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.